vs
FOCUS UNIVERSAL INC.（FCUV）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是FOCUS UNIVERSAL INC.的86950.6倍（$65.1M vs $749）。MESA LABORATORIES INC同比增速更快（3.6% vs -99.4%）。MESA LABORATORIES INC自由现金流更多（$18.0M vs $-1.4M）。过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -93.5%）
环球健康服务公司（UHS）是一家总部位于宾夕法尼亚州普鲁士王市的美国财富500强企业，主营医院运营与医疗保健服务。根据该公司2024年公布的数据，其全年总营收达到158亿美元，是美国医疗领域颇具规模的领军企业之一。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
FCUV vs MLAB — 直观对比
营收规模更大
MLAB
是对方的86950.6倍
$749
营收增速更快
MLAB
高出103.1%
-99.4%
自由现金流更多
MLAB
多$19.4M
$-1.4M
两年增速更快
MLAB
近两年复合增速
-93.5%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $749 | $65.1M |
| 净利润 | — | $3.6M |
| 毛利率 | -6912.1% | 64.2% |
| 营业利润率 | -119973.6% | 12.2% |
| 净利率 | — | 5.6% |
| 营收同比 | -99.4% | 3.6% |
| 净利润同比 | — | 316.6% |
| 每股收益（稀释后） | — | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCUVMLAB
| Q4 25 | $749 | $65.1M | ||
| Q3 25 | $28.7K | $60.7M | ||
| Q2 25 | $35.3K | $59.5M | ||
| Q1 25 | $190.3K | $62.1M | ||
| Q4 24 | $133.2K | $62.8M | ||
| Q3 24 | $74.2K | $57.8M | ||
| Q2 24 | $11.2K | $58.2M | ||
| Q1 24 | $179.5K | $58.9M |
净利润FCUVMLAB
| Q4 25 | — | $3.6M | ||
| Q3 25 | $-1.2M | $2.5M | ||
| Q2 25 | $-1.5M | $4.7M | ||
| Q1 25 | $-1.3M | $-7.1M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $1.4M | $3.4M | ||
| Q2 24 | $-1.4M | $3.4M | ||
| Q1 24 | $-1.3M | $-254.6M |
毛利率FCUVMLAB
| Q4 25 | -6912.1% | 64.2% | ||
| Q3 25 | -5.6% | 61.5% | ||
| Q2 25 | -35.1% | 62.0% | ||
| Q1 25 | 16.1% | 61.8% | ||
| Q4 24 | -95.4% | 63.3% | ||
| Q3 24 | 42.7% | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | 50.3% | 62.1% |
营业利润率FCUVMLAB
| Q4 25 | -119973.6% | 12.2% | ||
| Q3 25 | -4114.4% | 7.8% | ||
| Q2 25 | -4366.7% | 5.1% | ||
| Q1 25 | -668.3% | 2.4% | ||
| Q4 24 | -1507.4% | 9.2% | ||
| Q3 24 | -2353.8% | 6.1% | ||
| Q2 24 | -10965.3% | 9.6% | ||
| Q1 24 | -676.3% | -460.6% |
净利率FCUVMLAB
| Q4 25 | — | 5.6% | ||
| Q3 25 | -4065.6% | 4.1% | ||
| Q2 25 | -4261.7% | 8.0% | ||
| Q1 25 | -657.7% | -11.4% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | 1942.9% | 5.9% | ||
| Q2 24 | -12151.6% | 5.8% | ||
| Q1 24 | -732.9% | -432.2% |
每股收益（稀释后）FCUVMLAB
| Q4 25 | — | $0.65 | ||
| Q3 25 | — | $0.45 | ||
| Q2 25 | — | $0.85 | ||
| Q1 25 | $-0.17 | $-1.30 | ||
| Q4 24 | $-4.57 | $-0.31 | ||
| Q3 24 | $0.02 | $0.63 | ||
| Q2 24 | $-0.02 | $0.62 | ||
| Q1 24 | $-0.20 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.0M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $2.6M | $186.7M |
| 总资产 | $8.9M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资FCUVMLAB
| Q4 25 | $8.0M | $29.0M | ||
| Q3 25 | $454.4K | $20.4M | ||
| Q2 25 | $1.2M | $21.3M | ||
| Q1 25 | $2.2M | $27.3M | ||
| Q4 24 | $3.6M | $27.3M | ||
| Q3 24 | $5.4M | $24.3M | ||
| Q2 24 | $40.6K | $28.5M | ||
| Q1 24 | $114.1K | $28.2M |
总债务FCUVMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益FCUVMLAB
| Q4 25 | $2.6M | $186.7M | ||
| Q3 25 | $174.8K | $178.5M | ||
| Q2 25 | $845.6K | $172.5M | ||
| Q1 25 | $1.9M | $159.8M | ||
| Q4 24 | $3.2M | $155.2M | ||
| Q3 24 | $5.4M | $161.5M | ||
| Q2 24 | $1.2M | $150.7M | ||
| Q1 24 | $2.4M | $145.4M |
总资产FCUVMLAB
| Q4 25 | $8.9M | $434.8M | ||
| Q3 25 | $880.4K | $430.4M | ||
| Q2 25 | $1.7M | $435.7M | ||
| Q1 25 | $2.7M | $433.3M | ||
| Q4 24 | $4.1M | $433.3M | ||
| Q3 24 | $6.2M | $454.1M | ||
| Q2 24 | $4.9M | $440.4M | ||
| Q1 24 | $5.0M | $446.8M |
负债/权益比FCUVMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $-1.4M | $18.0M |
| 自由现金流率自由现金流/营收 | -186175.6% | 27.7% |
| 资本支出强度资本支出/营收 | 105.2% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | $-5.1M | $37.9M |
8季度趋势，按日历期对齐
经营现金流FCUVMLAB
| Q4 25 | $-1.4M | $18.8M | ||
| Q3 25 | $-1.1M | $8.2M | ||
| Q2 25 | $-1.4M | $1.9M | ||
| Q1 25 | $-1.2M | $12.7M | ||
| Q4 24 | $-997.9K | $18.1M | ||
| Q3 24 | $-1.9M | $5.3M | ||
| Q2 24 | $-829.9K | $10.7M | ||
| Q1 24 | $-892.1K | $12.9M |
自由现金流FCUVMLAB
| Q4 25 | $-1.4M | $18.0M | ||
| Q3 25 | $-1.1M | $7.1M | ||
| Q2 25 | $-1.4M | $884.0K | ||
| Q1 25 | $-1.2M | $11.9M | ||
| Q4 24 | $-1.0M | $17.3M | ||
| Q3 24 | $-1.9M | $3.5M | ||
| Q2 24 | $-834.6K | $9.9M | ||
| Q1 24 | $-897.1K | $12.3M |
自由现金流率FCUVMLAB
| Q4 25 | -186175.6% | 27.7% | ||
| Q3 25 | -3705.4% | 11.7% | ||
| Q2 25 | -4047.4% | 1.5% | ||
| Q1 25 | -653.6% | 19.2% | ||
| Q4 24 | -753.3% | 27.6% | ||
| Q3 24 | -2614.6% | 6.0% | ||
| Q2 24 | -7428.8% | 16.9% | ||
| Q1 24 | -499.8% | 21.0% |
资本支出强度FCUVMLAB
| Q4 25 | 105.2% | 1.1% | ||
| Q3 25 | 7.8% | 1.8% | ||
| Q2 25 | 4.8% | 1.7% | ||
| Q1 25 | 12.3% | 1.2% | ||
| Q4 24 | 4.1% | 1.3% | ||
| Q3 24 | 4.7% | 3.1% | ||
| Q2 24 | 41.8% | 1.5% | ||
| Q1 24 | 2.8% | 0.9% |
现金转化率FCUVMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.34× | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FCUV
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
